Clinical Trials Browser

Withdrawn × OTHER × naptumomab estafenatox × Clear all

NCT05894447 2024-04-12

Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers

Phase 1 Withdrawn

Carcinoma, Transitional Cell